PharmaJet's devices provide for fixed dose needle-free jet injection for all three tissue depths (IM, SC, & ID).

Sign up today and learn more about PHARMAJET Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.


PharmaJet is a user-friendly, inexpensive device for fluid injection into the body without a needle. Able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use and pass-along disease risk, the technology creates a positive ROI back for every injection. Unique in the field of jet injection because of its ability to reach all target tissues (IM, SC--0.5 mL, and ID--0.1 mL) accurately and comfortably, supported by wide regulatory claims (global and country specific) PharmaJet's platforms are the only commercially available devices that effectively address the 3 B annual immunization market. In addition to standard depth and dose delivery of any fluid, PharmaJet also has the ability to hyper-stimulate an improved immune response. The intradermal platform reduces the dose of vaccine by 60-80%, delivering into a 1.5-3mm tissue space in less than 1/10th of a second and achieving the same or superior immune response to a full intramuscular dose. For nucleic acid vaccines, both device platforms provide rapid delivery that helps negate the need for electroporation, while providing a several fold improved immune response versus needle based delivery. This is helping to facilitate vaccines gaining regulatory approval for solutions to pandemic threats and cancer vaccines, with a simple push and click.

Funding History

March 2011$4.2M
November 2011$3.4M
August 2012$2.8M
April 2013$2.5M
July 2013$5.2M
June 2015$3.8M
January 2016$3.0M
June 2017$3.0M
February 2018$0
January 2019$5.0M


Vice-Chairman, Global Business Development Officer, Co-Founder

Heather Callender-Potters

Chairman and Chief Executive Officer

Ron Lowy


Jeffrey Jordan

Chief Operating Officer

Chris Cappello

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: